MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584504 | Name: Epoprostenol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Epoprostenol is a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation.

Chemical Structure

Epoprostenol
Epoprostenol
CAS#35121-78-9

Theoretical Analysis

MedKoo Cat#: 584504

Name: Epoprostenol

CAS#: 35121-78-9

Chemical Formula: C20H32O5

Exact Mass: 352.2250

Molecular Weight: 352.47

Elemental Analysis: C, 68.15; H, 9.15; O, 22.70

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Epoprostenol; U 53,217; U 53217; U-53,217
IUPAC/Chemical Name
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-
InChi Key
KAQKFAOMNZTLHT-NXPDGUKVSA-N
InChi Code
InChI=1S/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19+/m0/s1
SMILES Code
CCCCC[C@H](O)/C=C/[C@@H]1[C@H]([C@@]2([H])C[C@H]1O)C/C(O2)=C/CCCC(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 352.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ahmad KA, Banales J, Henderson CL, Ramos SE, Brandt KM, Powers GC. Intravenous epoprostenol improves oxygenation index in patients with persistent pulmonary hypertension of the newborn refractory to nitric oxide. J Perinatol. 2018 Jul 25. doi: 10.1038/s41372-018-0179-7. [Epub ahead of print] PubMed PMID: 30046179. 2: Guan Z, Shen X, Zhang YJ, Li XG, Gao YF, Tan J, Yuan H, Liu JJ. Use of epoprostenol to treat severe pulmonary vasoconstriction induced by protamine in cardiac surgery. Medicine (Baltimore). 2018 Jul;97(28):e10908. doi: 10.1097/MD.0000000000010908. PubMed PMID: 29995750. 3: Navaratnam M, Williams GD, Shuttleworth P, Almond C, Maeda K. Epoprostenol Therapy for a Pediatric Patient With Subacute Heparin-Induced Thrombocytopenia and a Ventricular Assist Device Undergoing Heart Transplant: A Case Report. A A Pract. 2018 Jul 5. doi: 10.1213/XAA.0000000000000818. [Epub ahead of print] PubMed PMID: 29985837. 4: Akagi S, Matsubara H, Nakamura K, Ito H. Modern treatment to reduce pulmonary arterial pressure in pulmonary arterial hypertension. J Cardiol. 2018 Jun 10. pii: S0914-5087(18)30137-0. doi: 10.1016/j.jjcc.2018.04.014. [Epub ahead of print] Review. PubMed PMID: 29898864. 5: Ammar MA, Sasidhar M, Lam SW. Inhaled Epoprostenol Through Noninvasive Routes of Ventilator Support Systems. Ann Pharmacother. 2018 Jun 1:1060028018782209. doi: 10.1177/1060028018782209. [Epub ahead of print] PubMed PMID: 29890848. 6: Daizadeh I. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations. Ther Innov Regul Sci. 2018 Jan 1:2168479018778529. doi: 10.1177/2168479018778529. [Epub ahead of print] PubMed PMID: 29874936. 7: Wada H, Nakajima T, Suzuki H, Anazawa R, Narita T, Terada J, Yoshida S, Tatsumi K, Nakatani Y, Yoshino I. Pulmonary capillary hemangiomatosis diagnosed by pathology of explanted lungs: a unique etiology serves as a key of clinical diagnosis. Gen Thorac Cardiovasc Surg. 2018 May 26. doi: 10.1007/s11748-018-0950-x. [Epub ahead of print] PubMed PMID: 29804176. 8: Ibe T, Wada H, Sakakura K, Ugata Y, Ito M, Umemoto T, Momomura SI, Fujita H. A Case of Pulmonary Hypertension Associated with Idiopathic Hypereosinophilic Syndrome. Int Heart J. 2018 May 23. doi: 10.1536/ihj.17-419. [Epub ahead of print] PubMed PMID: 29794385. 9: Roberts KL, Shuster JE, Britt NS, Balsara KR, Graetz TJ, Helwani M, Itoh A, Tellor BR. Evaluation of Clinical Outcomes with Phosphodiesterase-5 Inhibitor Therapy for Right Ventricular Dysfunction After Left Ventricular Assist Device Implantation. ASAIO J. 2018 May 7. doi: 10.1097/MAT.0000000000000809. [Epub ahead of print] PubMed PMID: 29750687. 10: Kopeć G, Waligóra M, Stępniewski J, Podolec P. Indwelling central venous catheter occlusion during chronic epoprostenol infusion. J Heart Lung Transplant. 2018 Jul;37(7):938-940. doi: 10.1016/j.healun.2018.03.018. Epub 2018 Mar 30. PubMed PMID: 29731239. 11: Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM. Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. Chest. 2018 Apr 19. pii: S0012-3692(18)30571-3. doi: 10.1016/j.chest.2018.03.050. [Epub ahead of print] PubMed PMID: 29679599. 12: Levy M, Del Cerro MJ, Nadaud S, Vadlamudi K, Colgazier E, Fineman J, Bonnet D, Adatia I. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Int J Cardiol. 2018 Aug 1;264:153-157. doi: 10.1016/j.ijcard.2018.03.067. Epub 2018 Mar 15. PubMed PMID: 29650343. 13: Mihara K, Ogawa A, Matsubara H, Terao T, Ichikawa Y. Investigation of safety and efficacy of the new more thermostable formulation of Flolan (epoprostenol) in Japanese patients with pulmonary arterial hypertension (PAH)-An open-label, single-arm study. PLoS One. 2018 Apr 2;13(4):e0195195. doi: 10.1371/journal.pone.0195195. eCollection 2018. PubMed PMID: 29608587; PubMed Central PMCID: PMC5880383. 14: Koszutski M, Faure M, Guillaumot A, Gomez E, Mercy M, Chabot F, Chaouat A. [Tunnelled central venous catheter infection during treatment with epoprostenol]. Rev Mal Respir. 2018 Mar;35(3):324-327. doi: 10.1016/j.rmr.2017.03.037. Epub 2018 Mar 28. French. PubMed PMID: 29602480. 15: Ogawa A, Takahashi Y, Matsubara H. Clinical prediction score for identifying patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. J Cardiol. 2018 Sep;72(3):255-260. doi: 10.1016/j.jjcc.2018.02.009. Epub 2018 Mar 13. PubMed PMID: 29548663. 16: De Muynck B, Leys M, Cuypers J, Vanderschueren D, Delcroix M, Belge C. Hypocalcemia after Denosumab in a Pulmonary Hypertension Patient Receiving Epoprostenol. Respiration. 2018;95(2):139-142. doi: 10.1159/000481713. Epub 2017 Oct 30. PubMed PMID: 29485420. 17: Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, Hanna BD, Mercer-Rosa L. Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension. Pulm Circ. 2018 Apr-Jun;8(2):2045894018759247. doi: 10.1177/2045894018759247. Epub 2018 Feb 26. PubMed PMID: 29480089; PubMed Central PMCID: PMC5843105. 18: Gillis HC, Fischer G, Gupta S. Treatment of pulmonary hypertension with inhaled agents in the pediatric intensive care unit. Am J Health Syst Pharm. 2018 Feb 15;75(4):171-172. doi: 10.2146/ajhp170353. PubMed PMID: 29436464. 19: Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Ipilimumab induced digital vasculitis. J Immunother Cancer. 2018 Feb 12;6(1):12. doi: 10.1186/s40425-018-0321-2. PubMed PMID: 29433584; PubMed Central PMCID: PMC5809839. 20: Varela DL, Teleb M, El-Mallah W. Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review. Open Heart. 2018 Jan 9;5(1):e000744. doi: 10.1136/openhrt-2017-000744. eCollection 2018. PubMed PMID: 29344382; PubMed Central PMCID: PMC5761307.

View History

Fmoc-PEG2-NHS ester

Fmoc-PEG2-NHS ester

Featured